PCI Biotech announced that results from preclinical studies on tuberculosis performed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is 'Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice'.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.598 NOK | +3.77% | -1.36% | -23.72% |
1st Jan change | Capi. | |
---|---|---|
-23.72% | 5.2M | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Announces Publication of Preclinical Tuberculosis Results